Replies to post #38677 on Ariad Pharmaceuticals Inc fka ARIA

[grandma_of_jbraika]

FDA: 24% patients (median treatment duration 1.3 years) have experienced serious adverse vascular events.
2-Year Follow-Up Of The PACE Trial: "Serious cardiovascular, cerebrovascular, and peripheral vascular AEs occurred in 6%, 3%, and 2% of pts (drug-related: 2%, 1%, 1%)."

Who is right? Whom to believe?

Should not the FDA and Ariad explain the unbelievable discrepancy to the public scientifically, mathematically and statistically?

It seems that Araid dare not to challenge the FDA.